Barinthus Biotherapeutics plc
BRNS
$0.74
-$0.02-2.49%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 0.00 | 14.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 0.00 | 14.97M |
| Cost of Revenue | 4.26M | 8.29M | 8.09M | 7.78M | 8.48M |
| Gross Profit | -4.26M | -8.29M | -8.09M | -7.78M | 6.49M |
| SG&A Expenses | 16.06M | 24.67M | 35.01M | 30.14M | 38.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -557.00K | -565.00K | -848.00K | -1.59M | -1.52M |
| Total Operating Expenses | 31.79M | 43.12M | 57.73M | 54.52M | 68.62M |
| Operating Income | -31.79M | -43.12M | -57.73M | -54.52M | -53.65M |
| Income Before Tax | -41.97M | -52.50M | -66.63M | -76.06M | -69.55M |
| Income Tax Expenses | -167.00K | -169.00K | -175.00K | -115.00K | -47.00K |
| Earnings from Continuing Operations | -41.81 | -52.33 | -66.46 | -75.95 | -69.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 40.00K | 23.00K | 30.00K | 68.00K | 78.00K |
| Net Income | -41.77M | -52.31M | -66.43M | -75.88M | -69.43M |
| EBIT | -31.79M | -43.12M | -57.73M | -54.52M | -53.65M |
| EBITDA | -30.90M | -41.26M | -54.88M | -51.36M | -49.92M |
| EPS Basic | -1.02 | -1.29 | -1.64 | -1.88 | -1.73 |
| Normalized Basic EPS | -0.47 | -0.64 | -0.86 | -0.81 | -0.79 |
| EPS Diluted | -1.03 | -1.30 | -1.65 | -1.89 | -1.74 |
| Normalized Diluted EPS | -0.47 | -0.64 | -0.86 | -0.81 | -0.79 |
| Average Basic Shares Outstanding | 163.19M | 162.69M | 162.10M | 161.43M | 160.18M |
| Average Diluted Shares Outstanding | 163.19M | 162.69M | 162.10M | 161.43M | 160.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |